MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE Drug Patent Profile
Which patents cover Midazolam Hydrochloride Preservative Free, and what generic alternatives are available?
Midazolam Hydrochloride Preservative Free is a drug marketed by Fresenius Kabi Usa, Hospira, and Onesource Specialty. and is included in three NDAs.
The generic ingredient in MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE is midazolam hydrochloride. There is one drug master file entry for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the midazolam hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Midazolam Hydrochloride Preservative Free
A generic version of MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE was approved as midazolam hydrochloride by FRESENIUS KABI USA on June 20th, 2000.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE?
- What are the global sales for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE?
- What is Average Wholesale Price for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE?
Summary for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 7 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 15 |
| Patent Applications: | 1,883 |
| DailyMed Link: | MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE at DailyMed |
Recent Clinical Trials for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Nashwa Ahmed | PHASE4 |
| Fayoum University | Phase 1 |
| Tanta University | Early Phase 1 |
See all MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE clinical trials
Pharmacology for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
| Drug Class | Benzodiazepine |
US Patents and Regulatory Information for MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE
Midazolam Hydrochloride Preservative-Free Market Dynamics and Financial Trajectory
Midazolam hydrochloride preservative-free is a mature, multisource injectable generic used for procedural sedation, anesthesia induction, intensive-care sedation, and seizure management. Its commercial profile is driven by hospital purchasing contracts, supply reliability, manufacturing capacity, and shortage risk rather than patent exclusivity. The product has limited pricing power, no meaningful active U.S. patent barrier, and a financial trajectory tied to stable clinical demand and periodic supply disruptions.
What is the market position of preservative-free midazolam hydrochloride?
Midazolam hydrochloride is a short-acting benzodiazepine administered by injection, intramuscularly, orally in selected formulations, or intranasally in certain products. The preservative-free injectable product is primarily used in hospitals and outpatient procedural settings.
Common U.S. injectable strengths include:
| Product characteristic | Typical market configuration |
|---|---|
| Active ingredient | Midazolam hydrochloride |
| Dosage form | Injectable solution |
| Common concentrations | 1 mg/mL and 5 mg/mL |
| Container types | Single-dose vials, ampules, and prefilled syringes in selected channels |
| Preservative status | Preservative-free formulations are used when avoidance of antimicrobial preservatives is clinically required |
| Main customers | Hospitals, ambulatory surgery centers, emergency departments, intensive-care units |
| Primary procurement channel | Group purchasing organizations, hospital systems, wholesalers, and direct institutional contracts |
| Regulatory pathway | Abbreviated New Drug Application, or ANDA, for most generic suppliers |
Midazolam is a standard hospital sedative. Demand is recurring because the drug is embedded in procedural workflows and anesthesia protocols. The product is inexpensive per dose but strategically important because hospitals require continuous availability.
How large is the preservative-free midazolam market?
Public sources do not provide a reliable standalone revenue figure for the U.S. preservative-free midazolam hydrochloride segment. Manufacturers generally report sales at broader product-family or hospital-injectables levels rather than by concentration, preservative status, or individual NDC.
The market can be characterized through five commercial variables:
- Procedure volume in hospitals and ambulatory surgery centers.
- Number of active generic suppliers.
- Contract pricing and annual tender outcomes.
- Availability of sterile manufacturing capacity.
- Frequency and duration of shortages.
Midazolam demand is relatively defensive. Elective procedures affect volume, but emergency medicine, intensive care, anesthesia, and seizure treatment create a recurring base. During the COVID-19 pandemic, demand for injectable sedatives increased in mechanically ventilated patients, contributing to supply pressure for midazolam and competing sedatives.
The product’s financial value is therefore based more on volume and supply continuity than on high unit margins.
What drives the financial trajectory of midazolam hydrochloride preservative-free?
The financial trajectory is likely to remain mature and low-growth, with periodic revenue spikes during shortages and margin compression during periods of excess supply.
| Driver | Financial effect |
|---|---|
| Stable procedural demand | Supports recurring unit volume |
| Generic competition | Reduces average selling price |
| Hospital tendering | Transfers purchasing leverage to buyers |
| Sterile injectable manufacturing | Creates higher entry and compliance costs |
| Product shortages | Can increase realized prices and supplier share |
| New supplier entry | Pressures price and contract retention |
| Manufacturing interruptions | Can produce temporary revenue concentration among available suppliers |
| Alternative sedatives | Limits long-term pricing power |
| Concentration-specific demand | Supports portfolio sales across 1 mg/mL and 5 mg/mL presentations |
The main commercial asymmetry is that the drug is cheap but operationally important. A supplier with available inventory can gain share quickly during a shortage. That advantage may disappear when competitors restore production.
How do hospital contracts affect revenue?
Hospital systems and group purchasing organizations typically negotiate injectable generic prices through multiyear or annual contracts. Buyers may award volume based on:
- Delivered cost.
- Backorder history.
- Manufacturing redundancy.
- Fill-rate performance.
- Package configuration.
- Ability to supply multiple strengths.
- Regulatory inspection history.
- Wholesaler and distributor integration.
A manufacturer with a low list price but unreliable supply may lose share to a supplier offering a slightly higher price with consistent delivery. This makes operational execution a larger commercial differentiator than brand recognition.
When did midazolam lose patent exclusivity?
Midazolam is an off-patent product. Its original U.S. innovator protection expired well before the current generic market developed. The original branded product was marketed as Versed, and generic injectable products have been approved through ANDA pathways for many years.
No active composition-of-matter patent is expected to block generic competition for preservative-free injectable midazolam hydrochloride. The commercial issue is not patent expiry but the number and reliability of approved suppliers.
What patents protect midazolam hydrochloride preservative-free?
No material active U.S. patent estate is generally associated with the base active ingredient for current preservative-free injectable midazolam hydrochloride products.
Potentially relevant rights could include:
- Formulation patents.
- Container-closure patents.
- Prefilled syringe technology.
- Manufacturing-process patents.
- Device patents for specialized delivery systems.
- Method-of-use claims covering specific sedation protocols.
These rights are unlikely to create a broad barrier for standard midazolam hydrochloride injection supplied in conventional vials or ampules. Product-specific patent status must be assessed by NDC, ANDA number, dosage form, and delivery device.
What is the Orange Book status of preservative-free midazolam?
The FDA Orange Book primarily identifies approved drug products, therapeutic equivalence ratings, patents, and exclusivity associated with approved applications. Standard generic midazolam hydrochloride injection products are generally approved through ANDAs and compete through therapeutic equivalence rather than through new-drug exclusivity.
| Orange Book issue | Midazolam hydrochloride preservative-free assessment |
|---|---|
| Active ingredient exclusivity | None expected for the mature injectable generic |
| Composition-of-matter patent barrier | None material for ordinary injectable products |
| Paragraph IV litigation exposure | Low for the established generic market |
| Generic substitution | Depends on FDA therapeutic-equivalence designation and institutional purchasing rules |
| Listed patents | Usually not a meaningful barrier for conventional generic injection |
| New formulation risk | Higher if a product uses a novel device, concentration, or delivery mechanism |
The Orange Book is not the only relevant FDA source. The FDA’s Drugs@FDA database and National Drug Code Directory are necessary to identify active applications, dosage strengths, label revisions, and manufacturer-specific product status.[1,2]
Are there Paragraph IV challenges involving midazolam hydrochloride?
Paragraph IV litigation is not a central market issue for conventional preservative-free midazolam hydrochloride injection. Paragraph IV certifications are used when an ANDA applicant challenges listed patents associated with an approved reference product. For a mature, off-patent injectable with numerous generic suppliers, the commercial market is usually established before any current applicant can create a meaningful patent challenge.
The relevant risks are instead:
- FDA approval delays.
- Manufacturing deficiencies.
- Sterility failures.
- Container-closure defects.
- Supply interruptions.
- Drug-shortage allocation.
- Loss of a hospital contract.
A new delivery system or a differentiated formulation could create a separate patent dispute, but that would not necessarily affect the established vial market.
What formulation patents protect preservative-free midazolam?
Conventional preservative-free midazolam injection has limited formulation differentiation. The formulation challenge is technical rather than patent-driven.
Important product attributes include:
- Chemical stability in solution.
- Compatibility with infusion and injection materials.
- Control of particulate matter.
- Sterility assurance.
- Container-closure integrity.
- Concentration accuracy.
- Shelf life under labeled storage conditions.
- Resistance to precipitation or degradation.
- Compatibility with emergency and anesthesia workflows.
A preservative-free product may require tighter aseptic manufacturing controls because it cannot rely on antimicrobial preservatives to mitigate contamination risk. That requirement increases manufacturing complexity and validation cost. It does not automatically create enforceable exclusivity.
Which companies compete in the midazolam injection market?
The U.S. market has historically included major hospital-injectable suppliers and generic manufacturers such as Pfizer/Hospira, Hikma Pharmaceuticals, Fresenius Kabi, Sagent Pharmaceuticals, and other approved ANDA holders. The active supplier set changes as companies discontinue products, transfer applications, or alter manufacturing sites.
The competitive landscape is fragmented at the product level but can be concentrated during shortages. A supplier’s effective market share may therefore be much higher than its normal share when competing manufacturers experience backorders.
How does midazolam compare with competing sedatives?
| Drug | Principal advantage | Principal limitation | Competitive effect on midazolam |
|---|---|---|---|
| Midazolam | Familiar, rapid-onset benzodiazepine with amnestic effect | Respiratory depression and prolonged recovery in some patients | Baseline standard for procedural sedation |
| Lorazepam | Longer duration and broad hospital familiarity | Slower offset and formulation limitations | Competes in selected sedation and seizure settings |
| Diazepam | Established benzodiazepine with multiple uses | Less predictable administration profile in some settings | Substitution is clinically limited |
| Propofol | Rapid onset and recovery | Requires airway and hemodynamic monitoring | Strong competitor in anesthesia and deep sedation |
| Dexmedetomidine | Sedation with comparatively limited respiratory depression | Higher cost and hemodynamic effects | Competes in ICU and selected procedural settings |
| Ketamine | Analgesia, dissociation, and airway-related advantages in selected cases | Different psychotropic and cardiovascular profile | Competes in emergency and procedural sedation |
Midazolam retains a broad use case because it is familiar, inexpensive, and available in standard hospital protocols. Substitution is constrained by differences in onset, recovery, analgesia, respiratory effects, and monitoring requirements.
What FDA regulatory status applies to midazolam hydrochloride preservative-free?
Midazolam hydrochloride injection is an FDA-approved prescription product used in monitored clinical settings. The product labeling includes warnings concerning respiratory depression, airway obstruction, oxygen desaturation, apnea, hypotension, and enhanced central nervous system depression when combined with opioids or other sedatives.[3]
The regulatory burden is higher than for an oral generic because injectable products require validated sterile manufacturing and robust quality controls. FDA scrutiny focuses on:
- Aseptic processing.
- Sterility testing.
- Particulate control.
- Endotoxin limits.
- Container integrity.
- Stability data.
- Manufacturing-site compliance.
- Labeling and concentration accuracy.
A manufacturer can lose commercial supply without losing its ANDA if a facility experiences a warning letter, inspection finding, quality event, or production interruption.
What generic entry risks exist for midazolam?
Traditional generic entry risk is already realized. The market has moved beyond the question of whether generics can launch. The important question is whether additional suppliers can enter profitably without worsening price erosion.
Generic launch scenarios
| Scenario | Likely market effect |
|---|---|
| New supplier enters during normal supply | Lower contract prices and reduced incumbent share |
| New supplier enters during shortage | Rapid volume capture and improved hospital acceptance |
| Supplier exits after price compression | Higher concentration and potential supply instability |
| Existing supplier adds manufacturing capacity | Improved availability and weaker shortage premiums |
| New prefilled syringe product launches | Potential premium pricing in emergency and procedural channels |
| FDA quality action affects an incumbent | Temporary volume migration to remaining suppliers |
The highest entry barriers are sterile production, regulatory compliance, reliable raw-material sourcing, and customer qualification. Patent clearance is not the main barrier.
What patent litigation affects midazolam hydrochloride?
No major active patent litigation is expected to define the conventional preservative-free midazolam injection market. Litigation exposure is more likely to arise from:
- Product liability claims.
- Manufacturing-quality disputes.
- Contract disputes.
- False advertising or procurement claims.
- Patent disputes involving a novel delivery device.
- Litigation involving an alternative midazolam formulation rather than standard injection.
Patent risk should be evaluated separately for nasal, buccal, oral, autoinjector, and prefilled delivery products. Those products may involve device or formulation claims that do not apply to standard hospital vials.
Are there biosimilar risks for midazolam?
There is no biosimilar risk. Midazolam hydrochloride is a small-molecule drug, not a biologic. Competitive entry occurs through the generic ANDA pathway, not through the abbreviated biologics license application pathway.
The relevant competitive risks are generic price erosion, therapeutic substitution, hospital contracting, and supply reliability.
Are there licensing deals involving preservative-free midazolam?
Publicly disclosed licensing activity for standard preservative-free midazolam hydrochloride injection is limited. The product is mature and commonly supplied under manufacturer-owned ANDAs or commercial arrangements involving contract manufacturing, application transfers, or distribution agreements.
Licensing value is more likely in:
- Novel delivery systems.
- Combination products.
- Emergency-use devices.
- Regional distribution rights.
- Contract manufacturing arrangements.
- Portfolio acquisitions involving hospital injectables.
A conventional vial product generally has limited standalone licensing value because the active ingredient is off patent and procurement pricing is competitive.
What geographic markets are most attractive?
The strongest commercial markets are those with:
- High surgical and procedural volumes.
- Established hospital purchasing systems.
- Reliable reimbursement.
- Strict supply-quality requirements.
- Limited local sterile manufacturing capacity.
The United States is commercially important because of its large hospital injectable market and shortage sensitivity. Europe, Japan, and other regulated markets also have established midazolam use, but pricing, procurement rules, product concentrations, and approval requirements differ by country.
Geographic expansion may require:
- Local marketing authorization.
- Country-specific packaging.
- Stability data.
- Pharmacopoeial compliance.
- Qualified local distributors.
- Reimbursement or tender approval.
- Manufacturing-site recognition.
The commercial opportunity is usually incremental rather than transformational because midazolam is a mature international generic.
How strong is the patent estate for midazolam hydrochloride?
The patent estate is weak for standard preservative-free injectable midazolam. The market has the following profile:
| Patent category | Strength for conventional product |
|---|---|
| Active ingredient patent | Expired |
| Basic injectable formulation | Weak or expired |
| Standard vial presentation | Weak |
| Novel delivery device | Potentially stronger |
| Prefilled syringe configuration | Product-specific |
| Manufacturing process | Potentially relevant but difficult to enforce broadly |
| Method of use | Narrow and unlikely to block ordinary generic supply |
| Biosimilar exclusivity | Not applicable |
The principal commercial moat is manufacturing capability, not intellectual property.
What is the revenue outlook for preservative-free midazolam?
The expected financial trajectory is mature, stable, and margin-sensitive.
Near-term outlook
Revenue should track hospital procedure volumes, ICU utilization, emergency department demand, and supplier availability. Shortages can produce temporary price increases and disproportionate revenue for manufacturers with inventory.
Medium-term outlook
Pricing pressure is likely to continue as hospital buyers consolidate purchasing and suppliers compete for contracts. Unit growth may remain modest, while revenue growth depends on mix, supply events, and expansion into prefilled or differentiated presentations.
Long-term outlook
The conventional vial market should remain a low-growth generic business. Durable value is more likely for suppliers that offer:
- Multiple concentrations.
- Consistent fill rates.
- Redundant manufacturing sites.
- Strong regulatory records.
- Ready-to-administer presentations.
- Integrated hospital injectable portfolios.
A standalone midazolam product is unlikely to support high valuation multiples. A broader sterile-injectable portfolio can use midazolam as a recurring-volume product that strengthens hospital account relationships.
What manufacturing and intellectual-property barriers affect supply?
Manufacturing barriers are material even though patent barriers are limited. Sterile injectable production requires qualified facilities, specialized equipment, validated processes, and continuous regulatory compliance.
Key supply risks include:
- Shortage of active pharmaceutical ingredient.
- Limited sterile filling capacity.
- Glass vial or stopper shortages.
- Batch rejection.
- Contamination events.
- Site transfers.
- Import delays.
- Contract manufacturing dependence.
- Concentration-specific production constraints.
FDA shortage records should be reviewed by product presentation and manufacturer because availability may differ between 1 mg/mL and 5 mg/mL products or between vial and ampule formats.[4]
Key Takeaways
- Preservative-free midazolam hydrochloride is a mature generic injectable with recurring hospital demand.
- The product has no meaningful active composition-of-matter patent barrier.
- Paragraph IV litigation and biosimilar competition are not central risks.
- Financial performance depends on volume, contract pricing, manufacturing reliability, and shortage exposure.
- Sterile manufacturing capability is more important than patent ownership.
- Standard vial products have limited pricing power.
- Prefilled syringes, emergency-use formats, and differentiated delivery systems may command stronger commercial positioning.
- Revenue is likely stable to modestly declining under normal supply conditions, with temporary increases during shortages.
- The strongest suppliers are those with reliable inventory, multiple concentrations, regulatory-compliant facilities, and broad hospital-injectable portfolios.
FAQs
Is preservative-free midazolam hydrochloride a branded or generic drug?
It is primarily supplied as a generic injectable product. The original branded product was Versed, but current hospital supply is largely generic and manufacturer-specific.
Does midazolam hydrochloride injection have exclusivity?
No material active exclusivity is expected for conventional preservative-free midazolam hydrochloride injection. Competition is primarily governed by ANDA approvals and supplier availability.
Can hospitals substitute lorazepam for midazolam?
Clinicians may use lorazepam in selected settings, but the drugs differ in onset, duration, metabolism, administration characteristics, and recovery profile. Substitution is not automatic.
Why can a low-cost injectable drug experience shortages?
Sterile injectables depend on specialized manufacturing capacity, validated aseptic processes, and reliable container-closure components. A single manufacturing disruption can affect national supply.
Is preservative-free midazolam more valuable than preserved midazolam?
Preservative-free status may be clinically preferred in specific settings, but it does not by itself create substantial patent exclusivity or premium pricing. Commercial value depends on presentation, supply reliability, and customer contracts.
References
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). National Drug Code directory. https://www.accessdata.fda.gov/scripts/cder/ndc/
-
U.S. Food and Drug Administration. (2023). Midazolam injection prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Drug shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/
More… ↓
